ACHN News 7.64 07/14/2014 04:23:24 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Achillion Pharmaceuticals (ACHN) 7.64 $ACHN

Why American Apparel, Glu Mobile, and Achillion Pharmaceuticals Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 11, 4:15PM CDT
We haven't been able to say this often recently, but the broad-based S&P 500 limped into Friday's close with a modest gain, but still finished the week lower by nearly 1%. As is typical with most Fridays, economic data was fairly light....

Nasdaq stocks posting largest percentage increases
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis
PR Newswire - Thu Jul 10, 6:00AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Novavax Inc. (NASDAQ: NVAX), Dendreon Corp. (NASDAQ: DNDN) and Exelixis Inc. (NASDAQ: EXEL). Free technical research on ACHN, NVAX, DNDN and EXEL can be downloaded upon signing up at:

Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion
PR Newswire - Mon Jul 07, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), StemCells, Inc. (NASDAQ: STEM) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4482-100free.

The 5 Best Healthcare Stocks so Far in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 8:30AM CDT
Healthcare stocks put up impressive returns last year and are trumping the S&P 500 yet again this year. The S&P health care select index ETF (XLV) is up more than 10% this year and the iShares Nasdaq biotechnology ETF (IBB) has gained...

Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes
GlobeNewswire - Tue Jul 01, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that it has been added to the Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year.

3 Stocks With Eye-Popping Gains This Month
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 30, 2:12PM CDT
Shares in biotechnology companies can make breathtaking moves higher and lower on whims and whispers, and June was no exception. Following the sector's rollicking ride higher last year and dramatic sell-off in the first quarter, investors are right...

Achillion
at Investor's Business Daily - Fri Jun 20, 5:38PM CDT
Achillion (ACHN) shares rose 0.6% to 8.13 after R. W. Baird noted that Merck's (MRK) official tender offer indicated that there was another bidder for Idenix Pharmaceuticals, which means that a company is still looking for a nucleoside hepatitis C...

Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)...

The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene, Alexion and Biogen
PR Newswire - Thu Jun 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Idenix (Nasdaq:IDIX-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Nektar (Nasdaq:NKTR-Free Report), Orexigen (Nasdaq:OREX-Free Report), Celgene (Nasdaq:CELG-Free Report), Alexion (Nasdaq:ALXN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.

Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Jun 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BAC, ACHN, WMT, SUNE, and AMD.

Achillion Gets Massive Price Target Hike On HCV Drugs
at Investor's Business Daily - Mon Jun 16, 10:18PM CDT
Biotech Achillion Pharmaceuticals (ACHN) got another boost Monday when Maxim Group more than tripled its price target on the stock, sending shares up 21% on the stock market today. After having dinner with company executives, analyst Jason Kolbert...

Achillion gets price target hike
at Investor's Business Daily - Mon Jun 16, 5:56PM CDT
The biotech company's shares soared 20.9% to 7.82 after Maxim Group more than tripled its price target on Achillion Pharmaceuticals (ACHN) stock. Analyst Jason Kolbert increased his target to 22 from 6 on the potential of hepatitis C drug candidates,...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 35

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 28

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 15

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 44

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 24

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 29

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 33

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

CareDx and Dovetail Genomics Forge New Path in Transplant Solutions

Updated Category News Views 79

Partnership to Enhance HLA Typing Technology CareDx, Inc. (NASDAQ: CDNA), renowned for its pioneering precision medicine approach for transplant patients, has recently joined forces with Dovetail Genomics, a recognized leader in genomic solutions. This notable collaboration is set to introduce an Early Access Program designed for HLA laboratories, leveraging a unique...

Continue Reading
Pet Valu Holdings Secures C$150 Million Through Secondary Offering

Updated Category News Views 285

Pet Valu Holdings Hits Milestone with Recent Secondary Offering MARKHAM, Ontario — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), a prominent name in Canadian specialty retailing, has unveiled the successful completion of its secondary bought deal offering. This initiative has generated an impressive C$150 million through the sale of 5,200,000...

Continue Reading
SMCP Settles Legal Proceedings Over 15.9% Stake Dispute

Updated Category News Views 116

Overview of SMCP's Recent Legal Developments In a significant update, SMCP has received confirmation regarding the legal proceedings related to a notable 15.9% stake in its share capital. The London Court of Appeal has denied requests from Dynamic Treasure Group (DTG) to appeal the High Court's decision, which ruled the sale of shares to DTG as invalid. This ruling...

Continue Reading
Grit Real Estate Announces Important AGM Details for Shareholders

Updated Category News Views 91

Grit Real Estate Income Group's Upcoming AGM Grit Real Estate Income Group Limited, a pan-African leader in real estate, has made a significant announcement regarding its forthcoming Annual General Meeting (AGM). This event is set to take place on a Friday, specifically at 14h30 Mauritian time. Although the exact location is specified, the company invites all eligible...

Continue Reading
Petaluma Enriches Pet Nutrition with Dr. Sarah Dodd

Updated Category News Views 271

Petaluma Welcomes Dr. Sarah Dodd as Advisor and Formulator Petaluma, a forward-thinking sustainable pet nutrition company, is excited to announce the addition of Dr. Sarah Dodd as an Advisor and Formulator. Dr. Dodd is a renowned figure in the field of plant-based pet nutrition, bringing with her a wealth of experience to transform pet food for a sustainable and humane...

Continue Reading